– Agreement Includes the Option of up to an Additional $30 Million of Funding Contingent on Achievement of Certain Milestones NEW YORK, Nov. 24, 2021 /PRNewswire/ — Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced the placement of a $22.


Previous articleEntheon Biomedical Provides Update on Clinical and Preclinical DMT Programs
Next articlePTSF86 – Ayahuasca, Chronic Pain, and Legal Psilocybin, with Payton Nyquvest of Numinus